Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 75 entries
Sorted by: Best Match Show Resources per page
Heated, Humidified High-Flow Nasal Cannula vs Nasal Continuous Positive Airway Pressure for Respiratory Distress Syndrome of Prematurity: A Randomized Clinical Noninferiority Trial.

JAMA pediatrics

Lavizzari A, Colnaghi M, Ciuffini F, Veneroni C, Musumeci S, Cortinovis I, Mosca F.
PMID: 27532363
JAMA Pediatr. 2016 Aug 08; doi: 10.1001/jamapediatrics.2016.1243. Epub 2016 Aug 08.

IMPORTANCE: Heated, humidified high-flow nasal cannula (HHHFNC) has gained increasing popularity as respiratory support for newborn infants thanks to ease of use and improved patient comfort. However, its role as primary therapy for respiratory distress syndrome (RDS) of prematurity...

Cite
Lavizzari A, Colnaghi M, Ciuffini F, et al. Heated, Humidified High-Flow Nasal Cannula vs Nasal Continuous Positive Airway Pressure for Respiratory Distress Syndrome of Prematurity: A Randomized Clinical Noninferiority Trial. JAMA Pediatr. 2016;doi: 10.1001/jamapediatrics.2016.1243.
Lavizzari, A., Colnaghi, M., Ciuffini, F., Veneroni, C., Musumeci, S., Cortinovis, I., & Mosca, F. (2016). Heated, Humidified High-Flow Nasal Cannula vs Nasal Continuous Positive Airway Pressure for Respiratory Distress Syndrome of Prematurity: A Randomized Clinical Noninferiority Trial. JAMA pediatrics, . https://doi.org/10.1001/jamapediatrics.2016.1243
Lavizzari, Anna, et al. "Heated, Humidified High-Flow Nasal Cannula vs Nasal Continuous Positive Airway Pressure for Respiratory Distress Syndrome of Prematurity: A Randomized Clinical Noninferiority Trial." JAMA pediatrics vol. (2016). doi: https://doi.org/10.1001/jamapediatrics.2016.1243
Lavizzari A, Colnaghi M, Ciuffini F, Veneroni C, Musumeci S, Cortinovis I, Mosca F. Heated, Humidified High-Flow Nasal Cannula vs Nasal Continuous Positive Airway Pressure for Respiratory Distress Syndrome of Prematurity: A Randomized Clinical Noninferiority Trial. JAMA Pediatr. 2016 Aug 08; doi: 10.1001/jamapediatrics.2016.1243. Epub 2016 Aug 08. PMID: 27532363.
Copy Download .nbib Format: NLM
Targeted therapies and immunotherapy in non-small-cell lung cancer.

Ecancermedicalscience

Cortinovis D, Abbate M, Bidoli P, Capici S, Canova S.
PMID: 27433281
Ecancermedicalscience. 2016 Jun 23;10:648. doi: 10.3332/ecancer.2016.648. eCollection 2016.

Non-small-cell lung cancer is still considered a difficult disease to manage because of its aggressiveness and resistance to common therapies. Chemotherapy remains the gold standard in nearly 80% of lung cancers, but clinical outcomes are discouraging, and the impact...

Cite
Cortinovis D, Abbate M, Bidoli P, et al. Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedicalscience. 2016;10:648doi: 10.3332/ecancer.2016.648.
Cortinovis, D., Abbate, M., Bidoli, P., Capici, S., & Canova, S. (2016). Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedicalscience, 10648. https://doi.org/10.3332/ecancer.2016.648
Cortinovis, D, et al. "Targeted therapies and immunotherapy in non-small-cell lung cancer." Ecancermedicalscience vol. 10 (2016): 648. doi: https://doi.org/10.3332/ecancer.2016.648
Cortinovis D, Abbate M, Bidoli P, Capici S, Canova S. Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedicalscience. 2016 Jun 23;10:648. doi: 10.3332/ecancer.2016.648. eCollection 2016. PMID: 27433281; PMCID: PMC4929979.
Copy Download .nbib Format: NLM
Household Food Items Toxic to Dogs and Cats.

Frontiers in veterinary science

Cortinovis C, Caloni F.
PMID: 27047944
Front Vet Sci. 2016 Mar 22;3:26. doi: 10.3389/fvets.2016.00026. eCollection 2016.

Several foods that are perfectly suitable for human consumption can be toxic to dogs and cats. Food-associated poisoning cases involving the accidental ingestion of chocolate and chocolate-based products, Allium spp. (onion, garlic, leek, and chives), macadamia nuts, Vitis vinifera...

Cite
Cortinovis C, Caloni F. Household Food Items Toxic to Dogs and Cats. Front Vet Sci. 2016;3:26doi: 10.3389/fvets.2016.00026.
Cortinovis, C., & Caloni, F. (2016). Household Food Items Toxic to Dogs and Cats. Frontiers in veterinary science, 326. https://doi.org/10.3389/fvets.2016.00026
Cortinovis, Cristina, and Caloni, Francesca. "Household Food Items Toxic to Dogs and Cats." Frontiers in veterinary science vol. 3 (2016): 26. doi: https://doi.org/10.3389/fvets.2016.00026
Cortinovis C, Caloni F. Household Food Items Toxic to Dogs and Cats. Front Vet Sci. 2016 Mar 22;3:26. doi: 10.3389/fvets.2016.00026. eCollection 2016. PMID: 27047944; PMCID: PMC4801869.
Copy Download .nbib Format: NLM
Learning Disabilities in Extremely Low Birth Weight Children and Neurodevelopmental Profiles at Preschool Age.

Frontiers in psychology

Squarza C, Picciolini O, Gardon L, Giannì ML, Murru A, Gangi S, Cortinovis I, Milani S, Mosca F.
PMID: 27445952
Front Psychol. 2016 Jun 28;7:998. doi: 10.3389/fpsyg.2016.00998. eCollection 2016.

At school age extremely low birth weight (ELBW) and extremely low gestational age (ELGAN) children are more likely to show Learning Disabilities (LDs) and difficulties in emotional regulation. The aim of this study was to investigate the incidence of...

Cite
Squarza C, Picciolini O, Gardon L, et al. Learning Disabilities in Extremely Low Birth Weight Children and Neurodevelopmental Profiles at Preschool Age. Front Psychol. 2016;7:998doi: 10.3389/fpsyg.2016.00998.
Squarza, C., Picciolini, O., Gardon, L., Giannì, M. L., Murru, A., Gangi, S., Cortinovis, I., Milani, S., & Mosca, F. (2016). Learning Disabilities in Extremely Low Birth Weight Children and Neurodevelopmental Profiles at Preschool Age. Frontiers in psychology, 7998. https://doi.org/10.3389/fpsyg.2016.00998
Squarza, Chiara, et al. "Learning Disabilities in Extremely Low Birth Weight Children and Neurodevelopmental Profiles at Preschool Age." Frontiers in psychology vol. 7 (2016): 998. doi: https://doi.org/10.3389/fpsyg.2016.00998
Squarza C, Picciolini O, Gardon L, Giannì ML, Murru A, Gangi S, Cortinovis I, Milani S, Mosca F. Learning Disabilities in Extremely Low Birth Weight Children and Neurodevelopmental Profiles at Preschool Age. Front Psychol. 2016 Jun 28;7:998. doi: 10.3389/fpsyg.2016.00998. eCollection 2016. PMID: 27445952; PMCID: PMC4923155.
Copy Download .nbib Format: NLM
[ALK determination: liquid and tissue biopsy. Comparing techniques and effectiveness of alectinib in a controversial clinical case.].

Recenti progressi in medicina

Cortinovis D, Migliorati F, Pagni F.
PMID: 32658887
Recenti Prog Med. 2020 Jul-Aug;111(7):17e-20e. doi: 10.1701/3407.33930.

The next generation sequencing (NGS) applied to liquid biopsy is useful to determine the biomolecular identity of the prevalent neoplastic cell population. The sensitivity of ALK detection in liquid biopsy is comparable to that showed by the gold standard...

Cite
Cortinovis D, Migliorati F, Pagni F. Determinazione di ALK: tra biopsia liquida e tissutale. Tecniche a confronto ed efficacia di alectinib in un caso clinico controverso. [ALK determination: liquid and tissue biopsy. Comparing techniques and effectiveness of alectinib in a controversial clinical case.]. Recenti Prog Med. 2020;111(7):17e-20edoi: 10.1701/3407.33930.
Cortinovis, D., Migliorati, F., & Pagni, F. (2020). Determinazione di ALK: tra biopsia liquida e tissutale. Tecniche a confronto ed efficacia di alectinib in un caso clinico controverso. [ALK determination: liquid and tissue biopsy. Comparing techniques and effectiveness of alectinib in a controversial clinical case.]. Recenti progressi in medicina, 111(7), 17e-20e. https://doi.org/10.1701/3407.33930
Cortinovis, Diego, et al. "Determinazione di ALK: tra biopsia liquida e tissutale. Tecniche a confronto ed efficacia di alectinib in un caso clinico controverso." [ALK determination: liquid and tissue biopsy. Comparing techniques and effectiveness of alectinib in a controversial clinical case.]. Recenti progressi in medicina vol. 111,7 (2020): 17e-20e. doi: https://doi.org/10.1701/3407.33930
Cortinovis D, Migliorati F, Pagni F. Determinazione di ALK: tra biopsia liquida e tissutale. Tecniche a confronto ed efficacia di alectinib in un caso clinico controverso. [ALK determination: liquid and tissue biopsy. Comparing techniques and effectiveness of alectinib in a controversial clinical case.]. Recenti Prog Med. 2020 Jul-Aug;111(7):17e-20e. doi: 10.1701/3407.33930. Italian. PMID: 32658887.
Copy Download .nbib Format: NLM
Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Maurichi A, Miceli R, Eriksson H, Newton-Bishop J, Nsengimana J, Chan M, Hayes AJ, Heelan K, Adams D, Patuzzo R, Barretta F, Gallino G, Harwood C, Bergamaschi D, Bennett D, Lasithiotakis K, Ghiorzo P, Dalmasso B, Manganoni A, Consoli F, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Espeli V, Mangas C, Quaglino P, Ribero S, Broganelli P, Pellacani G, Longo C, Del Forno C, Borgognoni L, Sestini S, Pimpinelli N, Fortunato S, Chiarugi A, Nardini P, Morittu E, Florita A, Cossa M, Valeri B, Milione M, Pruneri G, Zoras O, Anichini A, Mortarini R, Santinami M.
PMID: 32167862
J Clin Oncol. 2020 May 10;38(14):1591-1601. doi: 10.1200/JCO.19.01902. Epub 2020 Mar 13.

PURPOSE: Thin melanomas (T1; ≤ 1 mm) constitute 70% of newly diagnosed cutaneous melanomas. Regional node metastasis determined by sentinel node biopsy (SNB) is an important prognostic factor for T1 melanoma. However, current melanoma guidelines do not provide clear...

Cite
Maurichi A, Miceli R, Eriksson H, et al. Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. J Clin Oncol. 2020;38(14):1591-1601doi: 10.1200/JCO.19.01902.
Maurichi, A., Miceli, R., Eriksson, H., Newton-Bishop, J., Nsengimana, J., Chan, M., Hayes, A. J., Heelan, K., Adams, D., Patuzzo, R., Barretta, F., Gallino, G., Harwood, C., Bergamaschi, D., Bennett, D., Lasithiotakis, K., Ghiorzo, P., Dalmasso, B., Manganoni, A., Consoli, F., Mattavelli, I., Barbieri, C., Leva, A., Cortinovis, U., Espeli, V., Mangas, C., Quaglino, P., Ribero, S., Broganelli, P., Pellacani, G., Longo, C., Del Forno, C., Borgognoni, L., Sestini, S., Pimpinelli, N., Fortunato, S., Chiarugi, A., Nardini, P., Morittu, E., Florita, A., Cossa, M., Valeri, B., Milione, M., Pruneri, G., Zoras, O., Anichini, A., Mortarini, R., & Santinami, M. (2020). Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(14), 1591-1601. https://doi.org/10.1200/JCO.19.01902
Maurichi, Andrea, et al. "Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 38,14 (2020): 1591-1601. doi: https://doi.org/10.1200/JCO.19.01902
Maurichi A, Miceli R, Eriksson H, Newton-Bishop J, Nsengimana J, Chan M, Hayes AJ, Heelan K, Adams D, Patuzzo R, Barretta F, Gallino G, Harwood C, Bergamaschi D, Bennett D, Lasithiotakis K, Ghiorzo P, Dalmasso B, Manganoni A, Consoli F, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Espeli V, Mangas C, Quaglino P, Ribero S, Broganelli P, Pellacani G, Longo C, Del Forno C, Borgognoni L, Sestini S, Pimpinelli N, Fortunato S, Chiarugi A, Nardini P, Morittu E, Florita A, Cossa M, Valeri B, Milione M, Pruneri G, Zoras O, Anichini A, Mortarini R, Santinami M. Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. J Clin Oncol. 2020 May 10;38(14):1591-1601. doi: 10.1200/JCO.19.01902. Epub 2020 Mar 13. PMID: 32167862; PMCID: PMC7213590.
Copy Download .nbib Format: NLM
Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy.

Frontiers in immunology

Perico N, Casiraghi F, Todeschini M, Cortinovis M, Gotti E, Portalupi V, Mister M, Gaspari F, Villa A, Fiori S, Introna M, Longhi E, Remuzzi G.
PMID: 29963053
Front Immunol. 2018 Jun 14;9:1359. doi: 10.3389/fimmu.2018.01359. eCollection 2018.

We report here the long-term clinical and immunological results of four living-donor kidney transplant patients given autologous bone marrow-derived mesenchymal stromal cells (MSCs) as part of a phase 1 study focused on the safety and feasibility of this cell...

Cite
Perico N, Casiraghi F, Todeschini M, et al. Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy. Front Immunol. 2018;9:1359doi: 10.3389/fimmu.2018.01359.
Perico, N., Casiraghi, F., Todeschini, M., Cortinovis, M., Gotti, E., Portalupi, V., Mister, M., Gaspari, F., Villa, A., Fiori, S., Introna, M., Longhi, E., & Remuzzi, G. (2018). Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy. Frontiers in immunology, 91359. https://doi.org/10.3389/fimmu.2018.01359
Perico, Norberto, et al. "Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy." Frontiers in immunology vol. 9 (2018): 1359. doi: https://doi.org/10.3389/fimmu.2018.01359
Perico N, Casiraghi F, Todeschini M, Cortinovis M, Gotti E, Portalupi V, Mister M, Gaspari F, Villa A, Fiori S, Introna M, Longhi E, Remuzzi G. Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy. Front Immunol. 2018 Jun 14;9:1359. doi: 10.3389/fimmu.2018.01359. eCollection 2018. PMID: 29963053; PMCID: PMC6014158.
Copy Download .nbib Format: NLM
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.

Clinical lung cancer

Cortinovis D, Grosso F, Carlucci L, Zucali PA, Pasello G, Tiseo M, Sperandi F, Hollander L, Galli F, Torri V, Rulli E, Canova S, Maconi A, Bidoli P, Ceresoli GL, D'Incalci M.
PMID: 32732073
Clin Lung Cancer. 2021 Jul;22(4):361-370.e3. doi: 10.1016/j.cllc.2020.06.028. Epub 2020 Jul 03.

INTRODUCTION: New therapeutic approaches in unresectable malignant pleural mesothelioma (MPM) are eagerly awaited. Trabectedin is an antitumor agent with an effect on cancer cell proliferation and a modulating action on tumor microenvironment. The ATREUS study explored the activity and...

Cite
Cortinovis D, Grosso F, Carlucci L, et al. Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study. Clin Lung Cancer. 2020;22(4):361-370.e3doi: 10.1016/j.cllc.2020.06.028.
Cortinovis, D., Grosso, F., Carlucci, L., Zucali, P. A., Pasello, G., Tiseo, M., Sperandi, F., Hollander, L., Galli, F., Torri, V., Rulli, E., Canova, S., Maconi, A., Bidoli, P., Ceresoli, G. L., D'Incalci, M. (2021). Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study. Clinical lung cancer, 22(4), 361-370.e3. https://doi.org/10.1016/j.cllc.2020.06.028
Cortinovis, Diego, et al. "Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study." Clinical lung cancer vol. 22,4 (2021): 361-370.e3. doi: https://doi.org/10.1016/j.cllc.2020.06.028
Cortinovis D, Grosso F, Carlucci L, Zucali PA, Pasello G, Tiseo M, Sperandi F, Hollander L, Galli F, Torri V, Rulli E, Canova S, Maconi A, Bidoli P, Ceresoli GL, D'Incalci M. Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study. Clin Lung Cancer. 2021 Jul;22(4):361-370.e3. doi: 10.1016/j.cllc.2020.06.028. Epub 2020 Jul 03. PMID: 32732073.
Copy Download .nbib Format: NLM
Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint .

EClinicalMedicine

Ruggenenti P, Caruso MR, Cortinovis M, Perna A, Peracchi T, Giuliano GA, Rota S, Brambilla P, Invernici G, Villa D, Diadei O, Trillini M, Natali G, Remuzzi G.
PMID: 34977512
EClinicalMedicine. 2021 Dec 14;43:101227. doi: 10.1016/j.eclinm.2021.101227. eCollection 2022 Jan.

BACKGROUND: Standard diet with normal calcium and reduced animal proteins and salt content reduces stone recurrence in calcium oxalate nephrolithiasis. Whether lemon juice supplementation further reduces recurrence rate is unknown.METHODS: In this single-centre, prospective, randomised, open, blinded endpoint trial...

Cite
Ruggenenti P, Caruso MR, Cortinovis M, et al. Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint . EClinicalMedicine. 2021;43:101227doi: 10.1016/j.eclinm.2021.101227.
Ruggenenti, P., Caruso, M. R., Cortinovis, M., Perna, A., Peracchi, T., Giuliano, G. A., Rota, S., Brambilla, P., Invernici, G., Villa, D., Diadei, O., Trillini, M., Natali, G., & Remuzzi, G. (2022). Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint . EClinicalMedicine, 43101227. https://doi.org/10.1016/j.eclinm.2021.101227
Ruggenenti, Piero, et al. "Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint ." EClinicalMedicine vol. 43 (2022): 101227. doi: https://doi.org/10.1016/j.eclinm.2021.101227
Ruggenenti P, Caruso MR, Cortinovis M, Perna A, Peracchi T, Giuliano GA, Rota S, Brambilla P, Invernici G, Villa D, Diadei O, Trillini M, Natali G, Remuzzi G. Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint . EClinicalMedicine. 2021 Dec 14;43:101227. doi: 10.1016/j.eclinm.2021.101227. eCollection 2022 Jan. PMID: 34977512; PMCID: PMC8683665.
Copy Download .nbib Format: NLM
Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study.

PloS one

Ruggenenti P, Di Marco F, Cortinovis M, Lorini L, Sala S, Novelli L, Raimondi F, Gastoldi S, Galbusera M, Donadelli R, Mele C, Piras R, Noris M, Portalupi V, Cappelletti L, Carrara C, Tomatis F, Bernardi S, Perna A, Peracchi T, Diadei O, Benigni A, Remuzzi G.
PMID: 34928990
PLoS One. 2021 Dec 20;16(12):e0261113. doi: 10.1371/journal.pone.0261113. eCollection 2021.

BACKGROUND: Complement activation contributes to lung dysfunction in coronavirus disease 2019 (COVID-19). We assessed whether C5 blockade with eculizumab could improve disease outcome.METHODS: In this single-centre, academic, unblinded study two 900 mg eculizumab doses were added-on standard therapy in...

Cite
Ruggenenti P, Di Marco F, Cortinovis M, et al. Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS One. 2021;16(12):e0261113doi: 10.1371/journal.pone.0261113.
Ruggenenti, P., Di Marco, F., Cortinovis, M., Lorini, L., Sala, S., Novelli, L., Raimondi, F., Gastoldi, S., Galbusera, M., Donadelli, R., Mele, C., Piras, R., Noris, M., Portalupi, V., Cappelletti, L., Carrara, C., Tomatis, F., Bernardi, S., Perna, A., Peracchi, T., Diadei, O., Benigni, A., & Remuzzi, G. (2021). Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PloS one, 16(12), e0261113. https://doi.org/10.1371/journal.pone.0261113
Ruggenenti, Piero, et al. "Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study." PloS one vol. 16,12 (2021): e0261113. doi: https://doi.org/10.1371/journal.pone.0261113
Ruggenenti P, Di Marco F, Cortinovis M, Lorini L, Sala S, Novelli L, Raimondi F, Gastoldi S, Galbusera M, Donadelli R, Mele C, Piras R, Noris M, Portalupi V, Cappelletti L, Carrara C, Tomatis F, Bernardi S, Perna A, Peracchi T, Diadei O, Benigni A, Remuzzi G. Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS One. 2021 Dec 20;16(12):e0261113. doi: 10.1371/journal.pone.0261113. eCollection 2021. PMID: 34928990; PMCID: PMC8687582.
Copy Download .nbib Format: NLM
New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)-Positive Cancer.

Cancers

Villa M, Sharma GG, Manfroni C, Cortinovis D, Mologni L.
PMID: 34680298
Cancers (Basel). 2021 Oct 14;13(20). doi: 10.3390/cancers13205149.

Cancer cells are characterized by high genetic instability, that favors tumor relapse. The identification of the genetic causes of relapse can direct next-line therapeutic choices. As tumor tissue rebiopsy at disease progression is not always feasible, noninvasive alternative methods...

Cite
Villa M, Sharma GG, Manfroni C, et al. New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)-Positive Cancer. Cancers (Basel). 2021;13(20)doi: 10.3390/cancers13205149.
Villa, M., Sharma, G. G., Manfroni, C., Cortinovis, D., & Mologni, L. (2021). New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)-Positive Cancer. Cancers, 13(20), . https://doi.org/10.3390/cancers13205149
Villa, Matteo, et al. "New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)-Positive Cancer." Cancers vol. 13,20 (2021). doi: https://doi.org/10.3390/cancers13205149
Villa M, Sharma GG, Manfroni C, Cortinovis D, Mologni L. New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)-Positive Cancer. Cancers (Basel). 2021 Oct 14;13(20). doi: 10.3390/cancers13205149. PMID: 34680298; PMCID: PMC8534237.
Copy Download .nbib Format: NLM
Recurrent idiopathic carotid and coronary artery vasospasm treated by stent implantations.

Journal of cardiovascular medicine (Hagerstown, Md.)

Buono A, Pero G, Bettari L, Pezzotti E, Cortinovis S, Gentili L, Mor D, Cuccia C, Maffeo D.
PMID: 34482326
J Cardiovasc Med (Hagerstown). 2021 Dec 01;22(12):e37-e40. doi: 10.2459/JCM.0000000000001247.

Arterial vasospasm is a well known cause of ischemia and, if prolonged, of parenchymal infarction. The clinical presentation varies according to the involved arterial district. We describe a rare case, which occurred in a young lady, of recurrent and...

Cite
Buono A, Pero G, Bettari L, et al. Recurrent idiopathic carotid and coronary artery vasospasm treated by stent implantations. J Cardiovasc Med (Hagerstown). 2021;22(12):e37-e40doi: 10.2459/JCM.0000000000001247.
Buono, A., Pero, G., Bettari, L., Pezzotti, E., Cortinovis, S., Gentili, L., Mor, D., Cuccia, C., & Maffeo, D. (2021). Recurrent idiopathic carotid and coronary artery vasospasm treated by stent implantations. Journal of cardiovascular medicine (Hagerstown, Md.), 22(12), e37-e40. https://doi.org/10.2459/JCM.0000000000001247
Buono, Andrea, et al. "Recurrent idiopathic carotid and coronary artery vasospasm treated by stent implantations." Journal of cardiovascular medicine (Hagerstown, Md.) vol. 22,12 (2021): e37-e40. doi: https://doi.org/10.2459/JCM.0000000000001247
Buono A, Pero G, Bettari L, Pezzotti E, Cortinovis S, Gentili L, Mor D, Cuccia C, Maffeo D. Recurrent idiopathic carotid and coronary artery vasospasm treated by stent implantations. J Cardiovasc Med (Hagerstown). 2021 Dec 01;22(12):e37-e40. doi: 10.2459/JCM.0000000000001247. PMID: 34482326.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 75 entries